Takeda Pharmaceutical Company halted production of a new type-2 diabetes drug due to dangerous side effects noted during experimentation.
Actos
Pioglitazone is a prescription drug used to treat diabetes. In 2008, it became one of the world’s best selling drugs despite safety concerns raised by the FDA. Many patients and their medical advisers were unaware of the relation between Actos and bladder cancer therefore, clinical studies were administered to analyze the linkage which resulted in cases of an 83% increased risk among users. Due to publicized risks and more affordable generic Actos alternatives, Takeda saw a steady decline in sales, which led to the TAK-875 roundtable.
TAK-875
Development of TAK-875 began after Takeda reached its Actos patent expiry in 2012. The pharmaceutical giant faced shaking sales and stock drops therefore, quickly began production for a replacement type-2 diabetes drug. As developing Fasiglifam clinical trials were conducted on diabetes patients, noted, unfortunate results included the high risk of liver damage which lead to the scrapping of TAK-875.
Fasiglifam was constructed to enhance insulin secretion by increasing the release of insulin from pancreatic beta cells when glucose and fatty acids increase in a patient’s bloodstream. Patients who were part of TAK-875’s experimental stage are currently being referred to professional medical investigators to begin appropriate therapy treatment.
If you or a loved one has been affected by the adverse side effects of Actos, contact an experienced attorney at The Byrd Law Firm to receive the proper legal representation you deserve.